Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent.
Micro and macrovascular complications occurring during hyperlipidemia are mostly attributed to haemostatic impairment and vascular endothelial dysfunction. Cholesteryl ester transfer protein (CETP) inhibitors have been emerged recently as promising hypocholesterolemic agents to confer protection against lipid-mediated atherosclerosis. Therefore, 10-dehydrogingerdione (DHGD), a novel CETP inhibitor isolated from ginger rhizomes, was selected as a natural product in the present study to illustrate its effect on haemostatic impairment associated with hyperlipidemia as compared to a currently used hypocholesterolemic agent, atorvastatin (ATOR). Rabbits were fed a high cholesterol diet (HCD) and divided into three groups. One group served as control group while the other groups received DHGD or ATOR. Dyslipidemic rabbits showed a significant increase in serum endothelin-1, ischemia modified albumin, plasminogen activator inhibitor-1, prothrombin fragments (1+2) and plasma fibrinogen along with a decrease of nitric oxide level in serum. Daily administration of ATOR or DHGD significantly decreased the aforementioned coagulation and ischemia biomarkers and increased serum nitric oxide. DHGD (natural) results seem to be more remarkable as compared to ATOR (synthetic).
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Sharkia Gov, Zagazig, 44519, Egypt, mmElseweidy@yahoo.com.
Mohamed Mahmoud
MM
El-Seweidy
Mervat El-Sayed
Mel-S
Asker
Sameih Ibrahim
SI
Eldahmy
Hebatallah Husseini
HH
Atteia
Mohamed Ahmed
MA
Abdallah
D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D050197:Atherosclerosis / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D000069059:Atorvastatin / Q000008:administration & dosage*; D001777:Blood Coagulation / Q000187:drug effects*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D004195:Disease Models, Animal; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D019332:Endothelin-1 / Q000097:blood; D004730:Endothelium, Vascular / Q000378:metabolism; D006139:Guaiacol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009569:Nitric Oxide / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011817:Rabbits; D016896:Treatment Outcome
C561631:(10)-dehydrogingerdione; D000924:Anticholesteremic Agents; D053480:Cholesterol Ester Transfer Proteins; D019332:Endothelin-1; D017395:Plasminogen Activator Inhibitor 1; D009569:Nitric Oxide; D006139:Guaiacol; D000069059:Atorvastatin